Talazoparib Loaded Solid Lipid Nanoparticles : Preparation, Characterization and Evaluation of the Therapeutic Efficacy In vitro
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
OBJECTIVE: In the present work, we report for the first time the therapeutic potential of talazoparib (BMN 673)-SLNs for the treatment of BRCA1 deficient Triple Negative Breast Cancer (TNBC). BMN 673-SLNs were produced by hot-homogenization technique and then characterized.
METHODS: The cytotoxic and apoptotic effects of BMN 673-SLNs compared with BMN 673 were determined on HCC1937BRCA1-/-, HCC1937-R resistant TNBC and MCF-10A control cell lines. BMN 673- SLNs were found to have reduced particle size (219.5 ± 1.45 nm) and thus more stable (-28.4 ± 2.52 mV) than BMN 673 (1652 ± 2.46 nm and -18.6 ± 0.45 mV) at 4°C.
RESULTS: In vitro cell line studies demonstrated that BMN 673-SLNs showed significant cytotoxic effects on HCC1937 (29.8%) and HCC1937-R cells (35.7%) at 10 nM for 12 days compared with BMN 673 (HCC1937 cells: 34.0% and HCC1937-R cells: 93.8% at 10 nM for 12 days) (p<0.05). Additionally, BMN 673-SLNs (40.1%) reduced the toxicity of BMN 673 (53.1%) on MCF-10A control cells thanks to unique physical properties.
CONCLUSION: The apoptotic rates in the 10 nM BMN 673-SLNs treatment (88.78% and 85.56%) for 12 days were significantly higher than those in 10 nM BMN 673 (82.6% and 25.86%) for 12 days in HCC1937 and HCC1937-R cells, respectively (p<0.01). Furthermore, these effects were consistent with the findings of colony formation, wound healing and calcein accumulation analysis. In conclusion, the therapeutic potential of BMN 673-SLNs provides a promising chemotherapeutic strategy for the treatment of drugresistant TNBC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Current drug delivery - 16(2019), 6 vom: 31., Seite 511-529 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Eskiler, Gamze Guney [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 23.03.2020 Date Revised 23.03.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1567201816666190515105532 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM297317245 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM297317245 | ||
| 003 | DE-627 | ||
| 005 | 20231225091733.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1567201816666190515105532 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0991.xml |
| 035 | |a (DE-627)NLM297317245 | ||
| 035 | |a (NLM)31113350 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Eskiler, Gamze Guney |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Talazoparib Loaded Solid Lipid Nanoparticles |b Preparation, Characterization and Evaluation of the Therapeutic Efficacy In vitro |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.03.2020 | ||
| 500 | |a Date Revised 23.03.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a OBJECTIVE: In the present work, we report for the first time the therapeutic potential of talazoparib (BMN 673)-SLNs for the treatment of BRCA1 deficient Triple Negative Breast Cancer (TNBC). BMN 673-SLNs were produced by hot-homogenization technique and then characterized | ||
| 520 | |a METHODS: The cytotoxic and apoptotic effects of BMN 673-SLNs compared with BMN 673 were determined on HCC1937BRCA1-/-, HCC1937-R resistant TNBC and MCF-10A control cell lines. BMN 673- SLNs were found to have reduced particle size (219.5 ± 1.45 nm) and thus more stable (-28.4 ± 2.52 mV) than BMN 673 (1652 ± 2.46 nm and -18.6 ± 0.45 mV) at 4°C | ||
| 520 | |a RESULTS: In vitro cell line studies demonstrated that BMN 673-SLNs showed significant cytotoxic effects on HCC1937 (29.8%) and HCC1937-R cells (35.7%) at 10 nM for 12 days compared with BMN 673 (HCC1937 cells: 34.0% and HCC1937-R cells: 93.8% at 10 nM for 12 days) (p<0.05). Additionally, BMN 673-SLNs (40.1%) reduced the toxicity of BMN 673 (53.1%) on MCF-10A control cells thanks to unique physical properties | ||
| 520 | |a CONCLUSION: The apoptotic rates in the 10 nM BMN 673-SLNs treatment (88.78% and 85.56%) for 12 days were significantly higher than those in 10 nM BMN 673 (82.6% and 25.86%) for 12 days in HCC1937 and HCC1937-R cells, respectively (p<0.01). Furthermore, these effects were consistent with the findings of colony formation, wound healing and calcein accumulation analysis. In conclusion, the therapeutic potential of BMN 673-SLNs provides a promising chemotherapeutic strategy for the treatment of drugresistant TNBC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Apoptosis | |
| 650 | 4 | |a PARP inhibitors | |
| 650 | 4 | |a Solid Lipid Nanoparticles(SLNs) | |
| 650 | 4 | |a Talazoparib (BMN 673) | |
| 650 | 4 | |a Triple Negative Breast Cancer (TNBC) | |
| 650 | 4 | |a cytotoxic effects. | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a BRCA1 Protein |2 NLM | |
| 650 | 7 | |a BRCA1 protein, human |2 NLM | |
| 650 | 7 | |a Lipids |2 NLM | |
| 650 | 7 | |a Phthalazines |2 NLM | |
| 650 | 7 | |a talazoparib |2 NLM | |
| 650 | 7 | |a 9QHX048FRV |2 NLM | |
| 700 | 1 | |a Cecener, Gulsah |e verfasserin |4 aut | |
| 700 | 1 | |a Dikmen, Gokhan |e verfasserin |4 aut | |
| 700 | 1 | |a Egeli, Unal |e verfasserin |4 aut | |
| 700 | 1 | |a Tunca, Berrin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current drug delivery |d 2004 |g 16(2019), 6 vom: 31., Seite 511-529 |w (DE-627)NLM159100232 |x 1875-5704 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2019 |g number:6 |g day:31 |g pages:511-529 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1567201816666190515105532 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2019 |e 6 |b 31 |h 511-529 | ||